{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:36:53Z","timestamp":1715819813758},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1701","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has granted regular approval to the oral kinase inhibitor tepotinib (Tepmetko \u2013 EMD Serono) for treatment of adults with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.<\/jats:p>","DOI":"10.58347\/tml.2024.1701f","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T16:30:11Z","timestamp":1715790611000},"page":"e73-e74","source":"Crossref","is-referenced-by-count":0,"title":["Tepotinib (Tepmetko) for NSCLC"],"prefix":"10.58347","volume":"66","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2024,4,29]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T16:30:11Z","timestamp":1715790611000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1701f"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":0,"journal-issue":{"issue":"1701","published-online":{"date-parts":[[2024,4,29]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1701f","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]}}}